Press Releases

Date Title and Summary
Toggle Summary Accuray Announces Convertible Notes Exchange and Subscription
SUNNYVALE, Calif. , May 6, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) today announced that it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2022 (the "2022 Notes") to exchange an aggregate of $82.1 million
Toggle Summary Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif. , May 6, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Jean-Philippe Pignol , M.D., Ph.D., the company's new Chief Medical & Technology Officer. As a material inducement to Dr.
Toggle Summary Geisinger becomes first in U.S. to treat cancer patients with Accuray Synchrony® technology on the Radixact® and CyberKnife® S7™ Systems to better target radiation treatments
WILKES-BARRE, Pa. and SUNNYVALE, Calif. , May 3, 2021 /PRNewswire/ --   Geisinger continues to bring advanced cancer care closer to home as it is the first hospital system in the U.S. to offer Accuray Incorporated's (NASDAQ: ARAY) newest Synchrony ®  technology on both the CyberKnife ® S7™  and
Toggle Summary Accuray Customers Achieve Top Scores in AAPM MArkerless Lung Target Tracking CHallenge (MATCH) Using Synchrony® Technology on the Radixact® and CyberKnife® Systems
- American Association of Physicists in Medicine (AAPM) Grand Challenge MATCH event was designed to evaluate the potential to track lung tumor motion without fiducial markers in real-time during radiation therapy - Results demonstrate exceptional accuracy is achievable with the Accuray-only
Toggle Summary Accuray Reports Third Quarter Fiscal 2021 Financial Results
SUNNYVALE, Calif. , April 27, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2021 ended March 31, 2021 .     Third Quarter Fiscal 2021 Summary Net revenue of $102.6 million including $24.9 million of system revenue in
Toggle Summary Accuray Appoints Jean-Philippe Pignol, M.D., Ph.D. as Chief Medical & Technology Officer
SUNNYVALE, Calif. , April 26, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY ) announced today the appointment of Jean-Philippe Pignol , M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021 . In this new role, Dr.
Toggle Summary Accuray Receives Shonin Approval for ClearRT™ Helical kVCT Imaging, CE Mark Expected by End of June; Expands Commercial Launch
Exceptional, Fan-beam Imaging for the Radixact® System Increases Radiation Treatment Options SUNNYVALE, Calif. , April 22, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the innovative ClearRT ™ helical fan-beam kVCT imaging* capability has now been in clinical use
Toggle Summary Accuray to Report Third Quarter Fiscal 2021 Financial Results on April 27, 2021
SUNNYVALE, Calif. , April 13, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2021, ended March 31, 2021, after the market close on Tuesday April 27, 2021. Management will host a conference call to review the results
Toggle Summary Accuray to Participate in the Cowen 41st Annual Health Care Conference
Company to take part in Fireside Chat Tuesday, March 2nd, 2021 at 11:50 am PT / 2:50 pm ET SUNNYVALE, Calif. , Feb. 23, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today announced its participation in the Cowen Annual Health Care Conference .
Toggle Summary Accuray Appoints Healthcare Executive and Physician Byron C. Scott to Board of Directors
SUNNYVALE, Calif. , Feb. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Byron C. Scott , M.D., MBA to the company's Board of Directors, effective as of February 12, 2021 . Dr. Scott brings significant experience as a physician executive with

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at and on the SEC's website at